A Phase I Dose Escalation Study of MK2206 in Combination With Standard Doses of Selected Chemotherapeutic or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of MK2206 in Combination With Standard Doses of Selected Chemotherapeutic or Targeted Agents in Patients With Locally Advanced or Metastatic Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2015

At a glance

  • Drugs Carboplatin; Docetaxel; Erlotinib; MK 2206; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 29 May 2012 Actual end date changed from May 2011 to May 2012 as reported by ClinicalTrials.gov.
    • 29 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Mar 2012 Actual patient number is 72 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top